Endo Settles Opioid Investigation With Oklahoma for $8.75M

Endo International subsidiaries Endo Pharmaceuticals and Par Pharmaceutical have executed a settlement agreement with the state of Oklahoma in which they agreed to pay $8.75 million.

• Settlement includes no admission of wrongdoing, fault or liability of any kind by Endo affiliates
• Endo EVP & Chief Legal Officer Matthew Maletta says “We believe this settlement reflects the fact that Endo was one of the first pharmaceutical manufacturers to voluntarily cease promotion of all opioid medications, along with voluntarily withdrawing one of its leading branded opioid medications from the market in 2017 and terminating all research and development of new opioid medications” ...